Curebound Adds Five Prominent Business Leaders to Board

New board members to accelerate impactful cancer research

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Curebound, a philanthropic organization that funds innovative cancer research, has announced the appointment of five prominent business leaders to its Board of Directors. The new board members - Gil Alvarado, Bret Gossett, David Hale, Anne Marbarger, and Tim Scott - bring cross-industry expertise to help accelerate Curebound's mission to fund collaborative cancer research with the power to save lives.

Why it matters

The addition of these accomplished leaders reflects the exceptional support and leadership uniting behind Curebound as the organization embarks on an exciting new chapter to further scale its operations and advance collaborative cancer research through a shared strategic vision.

The details

The new board members include David Hale, a successful serial entrepreneur and board leader in the life sciences industry; Tim Scott, President and CEO of Biocom California; Gil Alvarado, Chief Financial and Investment Officer of the Prebys Foundation; Bret Gossett, Executive Vice President and Co-Regional Market Director at Alexandria Real Estate Equities; and Anne Marbarger, a former CEO of Curebound who led the organization's transformation. Together, they bring decades of experience in biotech, philanthropy, real estate, and nonprofit leadership to help guide Curebound's future.

  • Curebound recently appointed Rick Valencia as its new board chair, succeeding Bill Koman, the organization's co-founder and outgoing chair.

The players

Curebound

A philanthropic organization that funds innovative cancer research and accelerates better prevention, detection, and treatments for cancer.

David Hale

Chairman and CEO of Hale BioPharma Ventures, a successful serial entrepreneur and board leader who has played a central role in building and guiding numerous life sciences companies.

Tim Scott

President and CEO of Biocom California, the largest biotechnology trade organization in the world, with 20+ years of experience founding and leading life science companies and supporting academic spinouts.

Gil Alvarado

Chief Financial and Investment Officer of the Prebys Foundation, with 30+ years as a senior financial executive in the nonprofit and foundation sector, bringing deep expertise in financial governance, impact investing, and institutional risk management.

Bret Gossett

Executive Vice President, Co-Regional Market Director & Head of Leasing at Alexandria Real Estate Equities San Diego, with 36 years of commercial real estate experience.

Anne Marbarger

Former CEO of Curebound, who led the transformation from Padres Pedal the Cause to Curebound, built partnerships with research partner institutions, launched the Concert for Cures series, and guided investment of $50+ million in innovative cancer research.

Got photos? Submit your photos here. ›

What they’re saying

“The addition of these prominent business leaders to our Board reflects the exceptional leadership that continues to unite behind Curebound at a pivotal moment in our journey. We are embarking on an exciting new chapter – working to further scale the organization and advance collaborative cancer research through a shared strategic vision.”

— Rick Valencia, Board Chair, Curebound (businesswire.com)

“These appointments will help drive Curebound's next phase of impact. These five talented leaders bring extraordinary experience, strategic insight, and a strong shared commitment to Curebound's mission. Their leadership strengthens our ability to invest in bold, collaborative science to accelerate promising research and cancer treatments for patients.”

— Robin Toft, Chief Executive Officer, Curebound (businesswire.com)

The takeaway

Curebound's addition of these prominent business leaders to its board reflects the organization's commitment to accelerating impactful cancer research through collaborative, mission-driven efforts. Their diverse expertise and shared vision will help Curebound scale its operations and deepen its impact in supporting innovative cancer treatments and therapies.